Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Going nuclear in metabolic and cardiovascular disease
Christopher K. Glass
Christopher K. Glass
Published March 1, 2006
Citation Information: J Clin Invest. 2006;116(3):556-560. https://doi.org/10.1172/JCI27913.
View: Text | PDF
Review Series

Going nuclear in metabolic and cardiovascular disease

  • Text
  • PDF
Abstract

Estrogen receptors, PPARs, and liver X receptors are members of the nuclear receptor superfamily of ligand-dependent transcription factors that regulate diverse aspects of development and homeostasis. Recent studies of the biologic roles of these receptors and their mechanisms of action have significantly advanced our understanding of transcriptional programs that control lipid and carbohydrate metabolism, immunity and inflammation, and wound repair. These findings provide insights into the therapeutic actions of existing drugs that target nuclear receptors and raise new possibilities for development of safer, more effective drugs for the prevention and treatment of metabolic and cardiovascular diseases. In this introduction to this Review series, underlying mechanisms that enable nuclear receptors to positively and negatively regulate gene expression are presented as background to the focused reviews on estrogen receptors, PPARs, liver X receptors, and the PPARγ coactivator-1 (PGC-1) family of coactivators.

Authors

Christopher K. Glass

×

Figure 3

Mechanisms of transcriptional activation and repression by steroid hormone and heterodimeric nuclear receptors.

Options: View larger image (or click on image) Download as PowerPoint
Mechanisms of transcriptional activation and repression by steroid hormo...
(A) Ligand-dependent transactivation. The binding of hormones or synthetic agonists causes the recruitment of coactivator complexes to the ligand-binding domain. Ligand-dependent recruitment of these factors is similar for heterodimeric receptors and steroid hormone receptors (not shown). For simplicity, only a single generic complex is illustrated. In general, ligand-dependent transcription of nuclear receptor target genes is associated with the recruitment of numerous coactivator complexes that act in a combinatorial or sequential manner. These complexes are associated with a number of enzymatic activities, including histone acetyltransferase (HAT), histone methyltransferase (HMT), and nucleosome remodeling (NRM) activities. Structurally distinct ligands may alter the pattern of recruitment of these factors, resulting in altered patterns of gene activation. (B) Active repression. A subset of heterodimeric nuclear receptors, including PPAR/RXR and LXR/RXR heterodimers, are capable of binding to REs in the absence of ligand and recruiting corepressor complexes that actively repress transcription. A number of corepressor complexes are associated with histone deacetylase (HDAC) activities, as well as histone methyltransferase and nucleosome remodeling activities that are generally distinct from those associated with coactivator complexes. HDM, histone demethylase. (C) SERM/antagonist–dependent repression. Some SERMs (shown here in gray), such as tamoxifen, and PPAR antagonists promote corepressor interactions with the ligand-binding domain, resulting in active repression in permissive cell types. (D) Ligand-dependent trans-repression. Many nuclear receptors, including glucocorticoid receptors, ERs, PPARs, and LXRs (indicated in blue), are capable of antagonizing signal-dependent activation of inflammatory response genes by transcription factors such as NF-κB.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts